Page 93 - Read Online

Della Corte et al. Hepatoma Res 2022;8:5 https://dx.doi.org/10.20517/2394-5079.2021.103 Page 13 of 15

25. Uchida M, Ishibashi M, Tomita N, Shinagawa M, Hayabuchi N, Okuda K. Hilar and suprapancreatic cholangiocarcinoma: value of 3D
angiography and multiphase fusion images using MDCT. AJR Am J Roentgenol 2005;184:1572-7. DOI PubMed
26. Matos C, Serrao E, Bali MA. Magnetic resonance imaging of biliary tumors. Magn Reson Imaging Clin N Am 2010;18:477-96, x. DOI
PubMed
27. Kim HJ, Lee SS, Byun JH, et al. Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic
metastasis detected at CT: a prospective comparison of diffusion-weighted imaging, gadoxetic acid-enhanced MR imaging, and a
combination of both MR techniques. Radiology 2015;274:712-22. DOI PubMed
28. Lee KH, Lee JM, Park JH, et al. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent
gadoxetic acid. Korean J Radiol 2013;14:894-904. DOI PubMed PMC
29. Shimada K, Isoda H, Hirokawa Y, Arizono S, Shibata T, Togashi K. Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-
weighted liver MRI for detection of small hepatic metastases. Eur Radiol 2010;20:2690-8. DOI PubMed
30. Olthof SC, Othman A, Clasen S, Schraml C, Nikolaou K, Bongers M. Imaging of cholangiocarcinoma. Visc Med 2016;32:402-10.
DOI PubMed PMC
31. Edge S. American Cancer Society. AJCC cancer staging handbook: from the AJCC cancer staging manual. New York: Springer; 2010.
32. Park HS, Lee JM, Choi JY, et al. Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography
versus MDCT with direct cholangiography. AJR Am J Roentgenol 2008;190:396-405. DOI PubMed
33. Jhaveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging 2015;42:1165-79. DOI PubMed
34. Cui XY, Chen HW. Role of diffusion-weighted magnetic resonance imaging in the diagnosis of extrahepatic cholangiocarcinoma.
World J Gastroenterol 2010;16:3196-201. DOI PubMed PMC
35. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011;54:1842-
52. DOI PubMed PMC
36. Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence-based approach to cholangiocarcinoma: a systematic
review of the current literature. J Am Coll Surg 2009;208:134-47. DOI PubMed
37. Joo I, Lee JM, Yoon JH. Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges.
Radiology 2018;288:7-13. DOI PubMed
38. Choi KS, Lee JM, Joo I, Han JK, Choi BI. Evaluation of perihilar biliary strictures: does DWI provide additional value to conventional
MRI? AJR Am J Roentgenol 2015;205:789-96. DOI PubMed
39. Choi EK, Yoo IeR, Kim SH, et al. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic
cholangiocarcinoma from benign disease. Clin Nucl Med 2013;38:e106-11. DOI PubMed
40. Wang S, Wu H, Wang Q, et al. 18F-FDG PET/CT in differentiating malignant from benign origins of obstructive jaundice.
Hepatobiliary Pancreat Dis Int 2015;14:516-22. DOI PubMed
41. Furukawa H, Ikuma H, Asakura-Yokoe K, Uesaka K. Preoperative staging of biliary carcinoma using 18F-fluorodeoxyglucose PET:
prospective comparison with PET+CT, MDCT and histopathology. Eur Radiol 2008;18:2841-7. DOI PubMed
42. Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of
gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004;8:90-7. DOI PubMed
43. Chong YS, Kim YK, Lee MW, et al. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular
carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol 2012;67:766-73. DOI PubMed
44. Inchingolo R, Maino C, Gatti M, et al. Gadoxetic acid magnetic-enhanced resonance imaging in the diagnosis of cholangiocarcinoma.
World J Gastroenterol 2020;26:4261-71. DOI PubMed PMC
45. Oliveira IS, Kilcoyne A, Everett JM, Mino-Kenudson M, Harisinghani MG, Ganesan K. Cholangiocarcinoma: classification,
diagnosis, staging, imaging features, and management. Abdom Radiol (NY) 2017;42:1637-49. DOI PubMed
46. Türkoğlu MA, Yamamoto Y, Sugiura T, et al. The favorable prognosis after operative resection of hypervascular intrahepatic
cholangiocarcinoma: a clinicopathologic and immunohistochemical study. Surgery 2016;160:683-90. DOI PubMed
47. Ariizumi S, Kotera Y, Takahashi Y, et al. Mass-forming intrahepatic cholangiocarcinoma with marked enhancement on arterial-phase
computed tomography reflects favorable surgical outcomes. J Surg Oncol 2011;104:130-9. DOI PubMed
48. Lee J, Kim SH, Kang TW, Song KD, Choi D, Jang KT. Mass-forming intrahepatic cholangiocarcinoma: diffusion-weighted imaging
as a preoperative prognostic marker. Radiology 2016;281:119-28. DOI PubMed
49. Koh J, Chung YE, Nahm JH, et al. Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-
enhanced MRI. Eur Radiol 2016;26:407-16. DOI PubMed
50. Asayama Y, Yoshimitsu K, Irie H, et al. Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic
cholangiocarcinoma. Radiology 2006;238:150-5. DOI PubMed
51. Kajiyama K, Maeda T, Takenaka K, Sugimachi K, Tsuneyoshi M. The significance of stromal desmoplasia in intrahepatic
cholangiocarcinoma: a special reference of ‘scirrhous-type’ and ‘nonscirrhous-type’ growth. Am J Surg Pathol 1999;23:892-902. DOI
PubMed
52. Pandey A, Pandey P, Ghasabeh MA, et al. Baseline volumetric multiparametric MRI: can it be used to predict survival in patients with
unresectable intrahepatic cholangiocarcinoma undergoing transcatheter arterial chemoembolization? Radiology 2018;289:843-53. DOI
PubMed
53. Yoo J, Kim JH, Bae JS, Kang HJ. Prediction of prognosis and resectability using MR imaging, clinical, and histopathological findings
in patients with perihilar cholangiocarcinoma. Abdom Radiol (NY) 2021;46:4159-69. DOI PubMed
54. Slakey DP. Radiofrequency ablation of recurrent cholangiocarcinoma. Am Surg 2002;68:395-7. PubMed
55. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol